Helicobacter Pylori Diagnostics Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

The Helicobacter pylori diagnostics market covers the tools, reagents, and services used to detect H. pylori bacterial infections, which affect roughly half the world's population and are a leading cause of peptic ulcers and stomach cancer. The global market is valued at approximately $731 million in 2025 and is expected to reach around $1.2 billion by 2034, growing at a compound annual rate of about 6 percent. The market spans multiple diagnostic technologies, including immunoassays, molecular methods, and point-of-care tests.

• •Valued at approximately $731 million in 2025; projected to reach ~$1.2 billion by 2034
• •Covers diagnostic tools for detecting H. pylori infections linked to ulcers and gastric cancer
• •Includes immunoassays, molecular diagnostics, and point-of-care testing technologies

Rising prevalence of H. pylori infections in developing regions, combined with growing clinical awareness of the bacterium's role in gastric diseases, is expanding testing volumes worldwide. Advancements in molecular diagnostics and point-of-care technologies are improving test accuracy, speed, and accessibility, encouraging broader adoption. Additionally, increasing healthcare spending and improved diagnostic infrastructure in emerging markets are supporting market expansion.

• •High infection prevalence in Asia-Pacific, Africa, and Latin America drives testing demand
• •Improved diagnostic technologies, especially molecular and POC tests, enable faster, more accurate detection
• •Growing awareness of H. pylori's link to gastric cancer and peptic ulcers increases screening rates

The market is segmented by product type into instruments, reagents, and services, with reagents typically representing the largest share due to their recurring use in testing workflows. By technology, immunoassays remain the most widely adopted, though molecular diagnostics are growing rapidly due to their superior accuracy and ability to detect antibiotic resistance. North America leads the global market, supported by advanced healthcare infrastructure, while the Asia-Pacific region is expected to see the fastest growth due to high infection prevalence and rising healthcare investment.

• •Segmented by type (instruments, reagents, services) and technology (immunoassays, molecular, POC)
• •North America is the largest market; Asia-Pacific is the fastest-growing region
• •The U.S. market alone is expected to grow from ~$279 million in 2024 to over $440 million by 2034

What are the recent trends and outlook?

Molecular diagnostic tests, particularly those capable of detecting antibiotic resistance alongside infection status, are expected to gain market share as treatment guidelines increasingly emphasize personalized therapy. Point-of-care testing is also becoming more prominent, driven by demand for rapid results in outpatient and resource-limited settings. Over the 2025-2034 period, the market is likely to see continued consolidation among major diagnostics firms and expanded geographic penetration into underdiagnosed regions.

• •Molecular diagnostics gaining share due to antibiotic resistance detection capabilities
• •Point-of-care tests expanding as demand for rapid, decentralized testing grows
• •Market expected to consolidate among major players while expanding into underdiagnosed regions